XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer

Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer

(2015) Fa-Xing Yu et al.   CELL

Identifying Drug-Target Selectivity of Small-Molecule CRM1/XPO1 Inhibitors by CRISPR/Cas9 Genome Editing

(2015) Jasper E. Neggers et al.   CHEMISTRY & BIOLOGY

Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway

(2015) Jung-Soon Mo et al.   NATURE CELL BIOLOGY

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies

(2015) Luping Lin et al.   NATURE GENETICS

YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression

(2015) Julien Fitamant et al.   Cell Reports

Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer

(2014) Avnish Kapoor et al.   CELL

KRAS and YAP1 Converge to Regulate EMT and Tumor Survival

(2014) Diane D. Shao et al.   CELL

XPO1 (CRM1) Inhibition Represses STAT3 Activation to Drive a Survivin-Dependent Oncogenic Switch in Triple-Negative Breast Cancer

(2014) Y. Cheng et al.   MOLECULAR CANCER THERAPEUTICS

Drugging the undruggable RAS: Mission Possible?

(2014) Adrienne D. Cox et al.   NATURE REVIEWS DRUG DISCOVERY

KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia

(2013) Julia Etchin et al.   BRITISH JOURNAL OF HAEMATOLOGY

Systematic Identification of Molecular Subtype-Selective Vulnerabilities in Non-Small-Cell Lung Cancer

(2013) Hyun Seok Kim et al.   CELL

Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia

(2012) R. Lapalombella et al.   BLOOD

The GATA2 Transcriptional Network Is Requisite for RAS Oncogene-Driven Non-Small Cell Lung Cancer

(2012) Madhu S. Kumar et al.   CELL

Nuclear Export of the NF-κB Inhibitor IκBα Is Required for Proper B Cell and Secondary Lymphoid Tissue Formation

(2011) Shelly M. Wuerzberger-Davis et al.   IMMUNITY

Proliferative potential and phenotypic analysis of long-term cultivated human granulosa cells initiated by addition of follicular fluid

(2011) Lenka Bruckova et al.   JOURNAL OF ASSISTED REPRODUCTION AND GENETICS

Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells

(2009) Claudia Scholl et al.   CELL

A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene

(2009) Ji Luo et al.   CELL

HER Family Receptor Abnormalities in Lung Cancer Brain Metastases and Corresponding Primary Tumors

(2009) M. Sun et al.   CLINICAL CANCER RESEARCH

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

(2009) David A. Barbie et al.   NATURE

Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma

(2009) Etienne Meylan et al.   NATURE

Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase

(2009) Michel DuPage et al.   Nature Protocols

Ultrafast and memory-efficient alignment of short DNA sequences to the human genome

(2009) Ben Langmead et al.   GENOME BIOLOGY

PIK3CA Mutations and Copy Number Gains in Human Lung Cancers

(2008) H. Yamamoto et al.   CANCER RESEARCH

An Oncogenomics-Based In Vivo RNAi Screen Identifies Tumor Suppressors in Liver Cancer

(2008) Lars Zender et al.   CELL